Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/158357
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Blasco, Lucía | - |
dc.contributor.author | Ambroa, Antón | - |
dc.contributor.author | López, Maria | - |
dc.contributor.author | Fernández García, Laura | - |
dc.contributor.author | Bleriot, Ines | - |
dc.contributor.author | Trastoy Pena, Rocío | - |
dc.contributor.author | Ramos Vivas, José | - |
dc.contributor.author | Coenye, Tom | - |
dc.contributor.author | Fernández Cuenca, Felipe | - |
dc.contributor.author | Vila Estapé, Jordi | - |
dc.contributor.author | Martínez Martínez, Luis | - |
dc.contributor.author | Rodríguez Baño, Jesús | - |
dc.contributor.author | Pascual, Alvaro | - |
dc.contributor.author | Cisneros, José Miguel | - |
dc.contributor.author | Pachón, Jerónimo | - |
dc.contributor.author | Bou, Germán | - |
dc.contributor.author | Tomás, María | - |
dc.date.accessioned | 2020-05-02T17:26:26Z | - |
dc.date.available | 2020-05-02T17:26:26Z | - |
dc.date.issued | 2019-11-12 | - |
dc.identifier.issn | 2076-2607 | - |
dc.identifier.uri | http://hdl.handle.net/2445/158357 | - |
dc.description.abstract | Phage therapy is an abandoned antimicrobial therapy that has been resumed in recent years. In this study, we mutated a lysogenic phage from Acinetobacter baumannii into a lytic phage (Ab105-2phi∆CI) that displayed antimicrobial activity against A. baumannii clinical strain Ab177_GEIH-2000 (isolated in the GEIH-REIPI Spanish Multicenter A. baumannii Study II 2000/2010, Umbrella Genbank Bioproject PRJNA422585, and for which meropenem and imipenem MICs of respectively, 32 μg/mL, and 16 μg/mL were obtained). We observed an in vitro synergistic antimicrobial effect (reduction of 4 log–7 log CFU/mL) between meropenem and the lytic phage in all combinations analyzed (Ab105-2phi∆CI mutant at 0.1, 1 and 10 MOI and meropenem at 1/4 and 1/8 MIC). Moreover, bacterial growth was reduced by 8 log CFU/mL for the combination of imipenem at 1/4 MIC plus lytic phage (Ab105-2phi∆CI mutant) and by 4 log CFU/mL for the combination of imipenem at 1/8 MIC plus lytic phage (Ab105-2phi∆CI mutant) at both MOI 1 and 10. These results were confirmed in an in vivo model (G. mellonella), and the combination of imipenem and mutant Ab105-2phi∆CI was most effective (p < 0.05). This approach could help to reduce the emergence of phage resistant bacteria and restore sensitivity to antibiotics used to combat multi-resistant strains of Acinetobacter baumannii. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/ 10.3390/microorganisms7110556 | - |
dc.relation.ispartof | Microorganisms, 2019, vol. 7, num. 11, p. 556 | - |
dc.relation.uri | http://dx.doi.org/10.3390/microorganisms7110556 | - |
dc.rights | cc by (c) Blasco et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Fonaments Clínics) | - |
dc.subject.classification | Malalties bacterianes | - |
dc.subject.classification | Resistència als medicaments | - |
dc.subject.other | Bacterial diseases | - |
dc.subject.other | Drug resistance | - |
dc.title | Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 701089 | - |
dc.date.updated | 2020-05-01T18:01:29Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31726694 | - |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
BlascoL_Microorganisms_2019.pdf | 1.6 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License